The role of Bisphosphonates in the prevention and treatment of Heterotopic Ossification following Spinal Cord Injury: A systematic review
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Pharmacologic prophylaxis for heterotopic ossification following spinal cord injury: A systematic review and meta-analysiClinical Neurology and Neurosurgery, 2020
- A systematic review of the therapeutic interventions for heterotopic ossification after spinal cord injurySpinal Cord, 2010
- Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosisBone, 2008
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 2007
- Amino-bisphosphonates in heterotopic ossification: first experience in five consecutive casesSpinal Cord, 2005
- Prevention of heterotopic ossification after spinal cord injury with COX-2 selective inhibitor (rofecoxib)Spinal Cord, 2004
- Neurogenic heterotopic ossification in spinal cord injurySpinal Cord, 2002
- Intravenous pamidronate attenuates bone density loss after acute spinal cord injuryArchives of Physical Medicine and Rehabilitation, 1999
- Evaluation and management of heterotopic ossification in patients with spinal cord injurySpinal Cord, 1997
- Heteretepic ossification following hip replacement or spinal cord injury. Two clinical studies with EHDPMetabolic Bone Disease and Related Research, 1981